Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

著者: Michael Haude, Raimund Erbel, Paul Erné, Stefan Verheye, Hubertus Degen, Dirk Böse, Paul Vermeersch, Inge Wijnbergen, Neil J. Weissman, Francesco Prati, Ron Waksman, Jacques Koolen - The Lancet 2013 被引用: 425